↓ Skip to main content

Ascending dose‐controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women

Overview of attention for article published in Obesity, May 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

blogs
2 blogs
twitter
5 X users
patent
19 patents
facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
57 Dimensions

Readers on

mendeley
103 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Ascending dose‐controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women
Published in
Obesity, May 2013
DOI 10.1002/oby.20356
Pubmed ID
Authors

T. E. Hughes, D. D. Kim, J. Marjason, J. Proietto, J. P. Whitehead, J. E. Vath

Abstract

Evaluate the safety and tolerability of beloranib, a fumagillin-class methionine aminopetidase-2 (MetAP2) inhibitor, in obese women over 4 weeks.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 103 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 103 100%

Demographic breakdown

Readers by professional status Count As %
Other 16 16%
Researcher 14 14%
Student > Bachelor 14 14%
Student > Master 12 12%
Student > Doctoral Student 7 7%
Other 17 17%
Unknown 23 22%
Readers by discipline Count As %
Medicine and Dentistry 36 35%
Agricultural and Biological Sciences 8 8%
Biochemistry, Genetics and Molecular Biology 6 6%
Pharmacology, Toxicology and Pharmaceutical Science 6 6%
Nursing and Health Professions 5 5%
Other 17 17%
Unknown 25 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 January 2019.
All research outputs
#1,404,459
of 24,571,708 outputs
Outputs from Obesity
#848
of 4,233 outputs
Outputs of similar age
#11,315
of 198,951 outputs
Outputs of similar age from Obesity
#43
of 211 outputs
Altmetric has tracked 24,571,708 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,233 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 37.6. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 198,951 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 211 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.